New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
08:06 EDTGENEGenetic Technologies downgraded to Sell from Buy at Ladenburg
Ladenburg downgraded Genetic Technologies two notches to Sell based on concerns it will not be able to secure patent license agreements due to the current patent landscape following the Mayo v Prometheus decision and the July 2012 USPTO decision to reexamination GENE’s ‘179 patent. As a result, the firm sees limited revenue contribution from its pipeline near-term. Price target cut to $1.60 from $7.50.
News For GENE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
05:39 EDTGENEGenetic Technologies launches BREVAGenplus in U.S.
Genetic Technologies announce the U.S. launch of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company's first generation product, BREVAGen. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman's five-year and lifetime risk of developing the disease. It is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. The test is directed towards Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ or ductal carcinoma in situ, and have one or more risk factors for developing breast cancer.
September 22, 2014
05:32 EDTGENEGenetic Technologies divests heritage Australian Genetics business for $2M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use